Login Register Cart 0
Generic placeholder image

Current Bioinformatics

Editor-in-Chief

ISSN (Print): 1574-8936
ISSN (Online): 2212-392X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Comprehensive Analysis of Key Proteins Involved in Radioresistance of Prostate Cancer by Integrating Protein-protein Interaction Networks

Author(s): Duocheng Qian, Quan Li, Yansong Zhu and Dujian Li*

Volume 16, Issue 1, 2021

Published on: 05 June, 2020

Page: [139 - 145] Pages: 7

DOI: 10.2174/1574893615999200605143510

Price: $65

Abstract

Background: Radioresistance remains a significant obstacle in the treatment of prostate cancer (PCa). The mechanisms underlying the radioresistance in PCa remained to be further investigated.

Methods: GSE53902 dataset was used in this study to identify radioresistance-related mRNAs. Protein-protein interaction (PPI) network was constructed based on STRING analysis. DAVID system was used to predict the potential roles of radioresistance-related mRNAs.

Results: We screened and re-annotated the GSE53902 dataset to identify radioresistance-related mRNAs. A total of 445 up-regulated and 1036 down-regulated mRNAs were identified in radioresistance PCa cells. Three key PPI networks consisting of 81 proteins were further constructed in PCa. Bioinformatics analysis revealed that these genes were involved in regulating MAP kinase activity, response to hypoxia, regulation of the apoptotic process, mitotic nuclear division, and regulation of mRNA stability. Moreover, we observed that radioresistance-related mRNAs, such as PRC1, RAD54L, PIK3R3, ASB2, FBXO32, LPAR1, RNF14, and UBA7, were dysregulated and correlated to the survival time in PCa.

Conclusion: We thought this study would be useful to understand the mechanisms underlying radioresistance of PCa and identify novel prognostic markers for PCa.

Keywords: Prostate cancer, radioresistance, biomarker, protein-protein interaction network, hypoxia, mRNA.

« Previous Next »
Graphical Abstract

[1]
Ginsburg KB, Auffenberg GB, Qi J, et al. Risk of becoming lost to follow-up during active surveillance for prostate cancer. Eur Urol 2018; 74(6): 704-7.
[http://dx.doi.org/10.1016/j.eururo.2018.08.010] [PMID: 30177290]
[2]
An J, Chervin AS, Nie A, Ducoff HS, Huang Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 2007; 26(5): 652-61.
[http://dx.doi.org/10.1038/sj.onc.1209830] [PMID: 16909121]
[3]
Hennessey D, Martin LM, Atzberger A, Lynch TH, Hollywood D, Marignol L. Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells. Urol Oncol 2013; 31(7): 1106-16.
[http://dx.doi.org/10.1016/j.urolonc.2011.10.008] [PMID: 22130126]
[4]
Chaiswing L, Weiss HL, Jayswal RD, Clair DKS, Kyprianou N. Profiles of radioresistance mechanisms in prostate cancer. Crit Rev Oncog 2018; 23(1-2): 39-67.
[http://dx.doi.org/10.1615/CritRevOncog.2018025946] [PMID: 29953367]
[5]
Zou Y, Yao S, Chen X, et al. LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells. Eur J Cell Biol 2018; 97(5): 369-78.
[http://dx.doi.org/10.1016/j.ejcb.2018.04.005] [PMID: 29773344]
[6]
Chen C, Wang K, Wang Q, Wang X. LncRNA HULC mediates radioresistance via autophagy in prostate cancer cells. Braz J Med Biol Res 2018; 51(6): e7080.
[http://dx.doi.org/10.1590/1414-431x20187080] [PMID: 29694502]
[7]
Chang ZW, Jia YX, Zhang WJ, et al. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res 2018; 37(1): 56.
[http://dx.doi.org/10.1186/s13046-018-0724-4] [PMID: 29530057]
[8]
Wu X, Scott H, Carlsson SV, et al. Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate 2019; 79(10): 1079-89.
[http://dx.doi.org/10.1002/pros.23817] [PMID: 31104332]
[9]
Chen X, Chen F, Ren Y, et al. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. J Cancer Res Clin Oncol 2019; 145(6): 1471-84.
[http://dx.doi.org/10.1007/s00432-019-02917-z] [PMID: 31020420]
[10]
Xie P, Yu H, Wang F, Yan F, He X. Inhibition of LOXL2 enhances the radiosensitivity of castration-resistant prostate cancer cells associated with the reversal of the EMT process. BioMed Res Int 2019; 2019: 4012590.
[http://dx.doi.org/10.1155/2019/4012590] [PMID: 30809541]
[11]
Chen Y, Shen Z, Zhi Y, et al. Long non-coding RNA ROR promotes radioresistance in hepatocelluar carcinoma cells by acting as a ceRNA for microRNA-145 to regulate RAD18 expression. Arch Biochem Biophys 2018; 645: 117-25.
[http://dx.doi.org/10.1016/j.abb.2018.03.018] [PMID: 29559320]
[12]
Yang T, Li S, Liu J, Yin D, Yang X, Tang Q. lncRNA-NKILA/NF-κB feedback loop modulates laryngeal cancer cell proliferation, invasion, and radioresistance. Cancer Med 2018; 7(5): 2048-63.
[http://dx.doi.org/10.1002/cam4.1405] [PMID: 29573243]
[13]
Cojoc M, Peitzsch C, Kurth I, et al. Aldehyde dehydrogenase is regulated by β-Catenin/TCF and promotes radioresistance in prostate cancer progenitor cells. Cancer Res 2015; 75(7): 1482-94.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-1924] [PMID: 25670168]
[14]
Zhang X, Sun S, Pu JK, et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis 2012; 48(1): 1-8.
[http://dx.doi.org/10.1016/j.nbd.2012.06.004] [PMID: 22709987]
[15]
Fillon M. Increased radiation intensity found to be safe for the treatment of prostate cancer. CA Cancer J Clin 2020; 70(2): 73-4.
[http://dx.doi.org/10.3322/caac.21595] [PMID: 31961947]
[16]
Devos B, Al Hajj Obeid W, Andrianne C, et al. Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes. World J Urol 2019; 37(8): 1507-15.
[http://dx.doi.org/10.1007/s00345-019-02640-x] [PMID: 30666400]
[17]
Abdollahi H, Mofid B, Shiri I, et al. Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer. Radiol Med 2019; 124(6): 555-67.
[http://dx.doi.org/10.1007/s11547-018-0966-4] [PMID: 30607868]
[18]
Huang T, Kim CK, Alvarez AA, et al. Increased Ezh2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate 2019; 79(10)
[http://dx.doi.org/10.1002/pros.23817]
[19]
Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008; 9(3): 288-96.
[http://dx.doi.org/10.1016/S1470-2045(08)70073-1] [PMID: 18308254]
[20]
Bartek J, Mistrik M, Bartkova J. Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer. Cancer Discov 2013; 3(11): 1222-4.
[http://dx.doi.org/10.1158/2159-8290.CD-13-0679] [PMID: 24203954]
[21]
Bekker-Jensen S, Rendtlew Danielsen J, Fugger K, et al. Herc2 coordinates ubiquitin-dependent assembly of DNA repair factors on damaged chromosomes. Nat Cell Biol 2010; 12(1): 80-6.
[http://dx.doi.org/10.1038/ncb2008]
[22]
Wang XC, Tian LL, Tian J, Jiang XY. Overexpression of SKP2 promotes the radiation resistance of esophageal squamous cell carcinoma. Radiat Res 2012; 177(1): 52-8.
[http://dx.doi.org/10.1667/RR2679.1] [PMID: 22077337]
[23]
Li D, Frazier M, Evans DB, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 2006; 24(11): 1720-8.
[http://dx.doi.org/10.1200/JCO.2005.04.4206] [PMID: 16520463]
[24]
Wang G, Yang X, Li C, Cao X, Luo X, Hu J. PIK3R3 induces epithelial-to-mesenchymal transition and promotes metastasis in colorectal cancer. Mol Cancer Ther 2014; 13(7): 1837-47.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0049] [PMID: 24837077]
[25]
Zhou H, Liu Y, Zhu R, et al. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation. Oncogene 2017; 36(23): 3312-21.
[http://dx.doi.org/10.1038/onc.2016.479] [PMID: 28068319]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy